HCV Treatment
NS5A Inhibitor Daclatasvir Has Dual Mode of Action Against Hepatitis C Virus
- Details
- Category: HCV Treatment
- Published on Wednesday, 20 February 2013 00:00
- Written by Loyola
The promising investigational hepatitis C virus (HCV) NS5A inhibitor daclatasvir targets 2 steps of the viral replication process, enabling very rapid HCV RNA reduction, according to a mathematical model described in the February 19, 2013, advance edition of Proceedings of the National Academy of Sciences.
Updated Boceprevir (Victrelis) Label Adds Data on Prior Null Responders
- Details
- Category: HCV Treatment
- Published on Friday, 15 February 2013 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) announced this week that the product label information for the hepatitis C virus (HCV) protease inhibitor boceprevir (brand name Victrelis) has been updated to include data on treatment of prior null responders.
Hepatitis C Re-treatment with Interferon Monotherapy Provides Little Benefit
- Details
- Category: HCV Treatment
- Published on Wednesday, 06 February 2013 00:00
- Written by Liz Highleyman
Long-term re-treatment with pegylated interferon monotherapy offers little or no clinical benefit -- even though it may suppress hepatitis C virus (HCV) levels and improve liver fibrosis -- but it can cause adverse events and may be associated with higher mortality, according to a systematic review from the Cochrane Library.
HCV Polymerase Inhibitor Mericitabine Boosts Interferon/Ribavirin Cure Rate
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 12 February 2013 00:00
- Written by Liz Highleyman
A 24-week response-guided triple regimen consisting of Roche's NS5B polymerase inhibitor mericitabine plus pegylated interferon and ribavirin produced a greater likelihood of sustained viral suppression than a 48-week course of pegylated interferon/ribavirin alone, according to a report in the January 28, 2013, online advance edition of Hepatology.
Sofosbuvir Combos Match or Beat Standard Hepatitis C Therapy For All Genotypes
- Details
- Category: HCV Treatment
- Published on Wednesday, 06 February 2013 00:00
- Written by Gilead Sciences
The experimental hepatitis C polymerase inhibitor sofosbuvir in an all-oral regimen with ribavirin worked as well as interferon-based therapy for previously untreated people with HCV genotypes 2 or 3, while adding sofosbuvir to pegylated interferon/ribavirin increased cure rates for those with more difficult-to-treat genotypes, Gilead Sciences announced this week.
Web Design and Development by